Clinical Trial Update: DOTA-TOC in Metastasized Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 2 trial evaluating DOTA-TOC in metastasized neuroendocrine tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• DOTA-TOC (DOTA-Tyr3-octreotate)

Snippet

Sponsor: University Hospital, Basel, Switzerland | Conditions: Neuroendocrine Tumors | Phase 2 | Status: COMPLETED